Endocrine Abstracts (2006) 11 P321

Long term safety of Atorvastatin and Fenofibrate therapy in patients with combined hyperlipidemia

A Azezli1, A Telci2, T Bayraktaroglu1, A Cikim1, A Uzum1, F Kutluturk1, S Tanyolac1 & Y Orhan1

1Istanbul University, Istanbul Faculty of Medicine, Endocrinology and Metabolism, Fatih/Istanbul, Turkey; 2Istanbul University, Istanbul Faculty of Medicine, Department of Biochemistry, Fatih/Istanbul, Turkey.

Combined hyperlipidemia is characterized by elevated levels of total cholesterol, low density lipoprotein (LDL), triglyceride and mild decrease in high density lipoprotein (HDL) cholesterol. It is difficult to achieve desirable decreases of LDL cholesterol, triglycerides and increasing of HDL cholesterol with monotherapy in patients with mixed hyperlipoproteinemia. This retrospective study was carried out to assess the safety atorvastatin-fenofibrate combination therapy.

One hundred-nine consecutive patients received atorvastatin 20 mg/day and micronised fenofibrate 200 mg/day combination for resistant hyperlipidemia to either agent therapy. Treatment continued for 2 years in all patients. To evaluate side effects, participant’s hepatic transaminase, creatine kinase (CK), blood urea nitrogen (BUN), and creatinine levels have been measured every three months. In our experience participants have been suffering insomnia and muscle weakness but there have not been encountered laboratory adverse effects in laboratory parameters.

In conclusion; our results suggested that combining atorvastatin and micronised fenofibrates in patient with combined hyperlipidemia could be used safely in Turkish hyperlipidemic patients.

Article tools

My recent searches

No recent searches.